Tedopi with pembrolizumab extended median PFS to 4.1 months in platinum-resistant ovarian cancer patients with no remaining standard treatment...

Aktis Oncology reports first-in-human data for AKY-2519 in B7-H3 tumors, showing predicted salivary gland dose of 4.2 Gy RBE...

China approves toripalimab plus disitamab vedotin for HER2+ urothelial cancer, doubling progression-free survival versus chemotherapy in Phase 3 trial.

RESP-X shows safety and reduced exacerbations in bronchiectasis study targeting Pseudomonas aeruginosa via PcrV inhibition.

TaiMed completes Phase 2b enrollment for TMB-365/380 HIV therapy without pre-treatment resistance screening, with interim analysis expected by end...

LUMA trial shows BIIB122 failed to slow Parkinson's despite achieving robust target engagement in 648 early-stage patients over 48–144...

Tedopi Plus Pembrolizumab achieves 47% risk reduction in recurrent ovarian cancer, extending median PFS to 4.1 months in chemotherapy-exhausted...

EMA's CHMP recommended 8 new medicines and 13 indication extensions in May 2026—including camizestrant for ESR1+ breast cancer and...

Zongertinib shows early symptom relief in LUNG-1 PRO trial, with physical functioning improvements appearing within one week of first-line...

Aktis Oncology reports lower salivary gland toxicity for AKY-2519 compared to approved PSMA-targeted radiopharmaceuticals in prostate cancer.